News / Taiwan / economic_daily
Lotus Pharmaceutical Reports 81.6% Revenue Surge in August, Driven by Alvogen Integration
Health Technology · Pharmaceuticals: Major · economic_daily · 2026-09-10
1795
Lotus Pharmaceutical announced an 81.67% year-over-year revenue increase for August, reaching NT$2.107 billion, fueled by strong B2B growth and the Alvogen merger.
What Happened
Revenue Growth Performance: Lotus Pharmaceutical reported a strong August consolidated revenue of NT$2.107 billion, marking an 81.67% year-over-year increase. For the first eight months of the year, cumulative revenue reached NT$220.52 billion, representing a 69% growth compared to the same period last year.
US Market Expansion: The company highlighted that its US operations have been a primary growth driver, with revenue reaching NT$13.083 billion through August, a 149% increase year-over-year. This segment now accounts for approximately 59% of the group's total consolidated revenue.
Regional and B2B Contributions: Asian operations remained stable, contributing NT$7.185 billion to the total revenue, representing about 33% of the group's share. Meanwhile, the B2B segment saw a significant 216% year-over-year growth, contributing NT$1.784 billion, or 8% of the total revenue.
Product Launch Strategy: The company's performance is bolstered by the successful global launch of key products. Specifically, the rollout of Nintedanib in Europe and North America, alongside Enzalutamide in Brazil, Canada, and South Korea, has provided substantial momentum for the firm's ongoing expansion.